查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1535663

胰臟癌診斷市場- 副產品（儀器、消耗品）、測試類型（影像[CT、MRI、超音波、PET]、活體組織切片、血液檢查[肝功能、腫瘤標記]）、癌症類型（外分泌、內分泌）、末端-使用-全球預測（2024 - 2032）

Pancreatic Cancer Diagnostic Market - By Product (Instruments, Consumables), Test Type (Imaging [CT, MRI, Ultrasound, PET], Biopsy, Blood Test [Liver Function, Tumor Marker]), Cancer Type (Exocrine, Endocrine), End-use- Global Forecast (2024 - 2032)
出版日期: | 出版商: Global Market Insights Inc. | 英文 298 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

在胰臟癌盛行率上升的推動下，全球胰臟癌診斷市場在 2024 年至 2032 年期間複合年成長率將達到 9.1%。據世界衛生組織稱，到 2030 年，胰腺癌病例預計將增加 55%。基於生物標記的測試、液體活體組織切片以及內視鏡超音波和 MRI 等成像技術等創新提高了早期檢出率，考慮到胰腺癌的侵襲性，這一點至關重要。這些進步提高了診斷準確性並實現個人化治療計劃，增加了對複雜工具的需求。

癌症研究資金和投資的增加也推動了市場的成長。政府和私人組織正在大力投資開發和改進診斷方法。例如，美國國家癌症研究所將在 2023 年撥款超過 60 億美元用於癌症研究。此外，不斷成長的老年人口更容易患胰臟癌，這凸顯了對先進診斷解決方案的需求。

整個胰臟癌診斷產業根據產品、測試類型、癌症類型、最終用途和地區進行分類。

活體組織切片部分預計在 2032 年之前獲得顯著的發展，這主要是因為它們在確認疾病的存在和階段方面發揮關鍵作用。活體組織切片測試，特別是細針抽吸和空心針活體組織切片，為準確診斷提供了必要的明確的組織病理學證據。隨著影像引導活體組織切片技術的進步，這些手術的精確度和安全性顯著提高。此外，對個人化醫療的日益重視需要對腫瘤組織進行詳細的遺傳和分子分析，而這些分析只能透過活體組織切片樣本獲得。

由於專注於開創性研發計劃，預計到 2032 年，癌症研究機構部門將佔據顯著的市場佔有率。這些研究所處於發現新型生物標記、完善診斷技術以及開發提高早期檢測和診斷準確性的尖端技術的前沿。透過進行廣泛的臨床試驗和轉化研究，癌症研究機構促進了創新診斷工具的引入。此外，他們與生物技術公司和醫療保健提供者的合作加速了這些先進診斷技術在臨床環境中的採用。這些機構的研究成果不斷湧入，不僅推動了技術進步，而且還創造了診斷實踐持續改進和適應的環境。

在醫療保健支出增加、癌症診斷意識提高以及醫療技術進步的推動下，到 2032 年，亞太地區胰臟癌診斷產業將錄得強勁的複合年成長率。由於人口老化和生活方式的改變，胰臟癌的發生率較高，這促使對有效診斷解決方案的需求更大。此外，旨在改善癌症護理基礎設施的政府舉措以及能夠獲得更好醫療服務的新興中產階級的出現也有助於市場擴張。充滿活力的製藥和生技產業，加上對研發的高度重視，將進一步塑造區域市場動態。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

  • 產業生態系統分析
  • 產業影響力
    • 成長動力
      • 胰臟癌盛行率增加
      • 診斷技術的進步
      • 全球醫療保健支出不斷成長
      • 人們對早期癌症檢測的認知不斷提高
    • 產業陷阱與挑戰
      • 嚴格的監管場景
      • 診斷測試成本高
  • 成長潛力分析
  • 報銷場景
  • 監管環境
  • 技術景觀
    • 核心技術
    • 鄰近技術
  • 2023 年定價分析
    • 按地區
    • 按關鍵人物
  • 未來市場趨勢
  • 波特的分析
  • PESTEL分析

第 4 章：競爭格局

  • 介紹
  • 公司市佔率分析
  • 公司矩陣分析
  • 主要市場參與者的競爭分析
  • 競爭定位矩陣
  • 戰略儀表板

第 5 章：市場估計與預測：按產品分類，2021 - 2032 年

  • 主要趨勢
  • 儀器儀表
  • 耗材

第 6 章：市場估計與預測：按測試類型，2021 - 2032

  • 主要趨勢
  • 影像學檢查
    • CT掃描
    • 核磁共振成像
    • 超音波
    • 寵物
    • 其他影像學檢查
  • 活體組織切片
  • 驗血
    • 肝功能檢查
    • 腫瘤標記
    • 其他血液檢查
  • 其他測試類型

第 7 章：市場估計與預測：按癌症類型，2021 - 2032 年

  • 主要趨勢
  • 外分泌
    • 腺癌
    • 鱗狀細胞癌
    • 腺鱗癌
    • 膠體癌
  • 內分泌

第 8 章：市場估計與預測：按最終用途，2021 - 2032 年

  • 主要趨勢
  • 醫院和診所
  • 診斷實驗室
  • 診斷影像中心
  • 癌症研究機構

第 9 章：市場估計與預測：按地區分類，2021 - 2032 年

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 荷蘭
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 亞太地區其他地區
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 拉丁美洲其他地區
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區

第 10 章：公司簡介

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • ASURAGEN, INC.
  • Becton, Dickinson and Company
  • BioMarker Strategies
  • Canon Inc.
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd.
  • GE HealthCare Technologies Inc.
  • Hitachi, Ltd.
  • Illumina, Inc.
  • Koninklijke Philips N.V.
  • Myriad Genetics, Inc.
  • Prestige Biopharma Limited (PBP)
  • QIAGEN N.V.
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
簡介目錄
Product Code: 9826

The global pancreatic cancer diagnostic market will record 9.1% CAGR over 2024-2032, driven by the rising prevalence of pancreatic cancer. According to the World Health Organization, pancreatic cancer cases are expected to rise by 55% by 2030. Sedentary lifestyles and high-fat, low-fiber diets have contributed to this increase in cases, pushing the demand for advanced diagnostic tools. Innovations such as biomarker-based tests, liquid biopsies, and imaging techniques like endoscopic ultrasound and MRI have improved early detection rates, which is crucial given the aggressive nature of pancreatic cancer. These advancements enhance diagnostic accuracy and enable personalized treatment plans, increasing the demand for sophisticated tools.

Increased funding and investment in cancer research is also driving market growth. Governments and private organizations are investing heavily in developing and improving diagnostic methods. For instance, the National Cancer Institute allocated over $6 billion for cancer research in 2023. Public awareness campaigns about early diagnosis and regular screenings have led to higher patient participation in diagnostic procedures. Additionally, the growing elderly population, more susceptible to pancreatic cancer, underscores the need for advanced diagnostic solutions.

The overall pancreatic cancer diagnostic industry is classified based on product, test type, cancer type, end use, and region.

The biopsy segment is poised for significant traction through 2032, primarily due to their critical role in confirming the presence and stage of the disease. Biopsy tests, particularly fine-needle aspiration and core needle biopsies, provide definitive histopathological evidence necessary for accurate diagnosis. With advancements in imaging-guided biopsy techniques, the precision and safety of these procedures have significantly improved. Additionally, the growing emphasis on personalized medicine necessitates detailed genetic and molecular profiling of tumor tissues, which can only be obtained through biopsy samples.

The cancer research institutes segment is anticipated to hold a notable market share by 2032, due to focus on pioneering R&D initiatives. These institutes are at the forefront of discovering novel biomarkers, refining diagnostic techniques, and developing cutting-edge technologies that enhance early detection and diagnosis accuracy. By conducting extensive clinical trials and translational research, cancer research institutes facilitate the introduction of innovative diagnostic tools. Moreover, their collaborations with biotechnology firms and healthcare providers accelerate the adoption of these advanced diagnostics in clinical settings. The continual influx of research findings from these institutes not only drives technological advancements but also fosters an environment of ongoing improvement and adaptation in diagnostic practices.

Asia Pacific pancreatic cancer diagnostic industry will record a strong CAGR through 2032, driven by increasing healthcare expenditures, rising awareness of cancer diagnostics, and advancements in medical technology. There is a higher incidence rate of pancreatic cancer due to aging populations and lifestyle changes, prompting greater demand for effective diagnostic solutions. Additionally, government initiatives aimed at improving cancer care infrastructure and the presence of a burgeoning middle class with access to better healthcare services contribute to market expansion. The dynamic pharmaceutical and biotech sectors, coupled with a strong emphasis on R&D will further shape the regional market dynamics.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing prevalence of pancreatic cancer
      • 3.2.1.2 Advancements in diagnostic technologies
      • 3.2.1.3 Growing healthcare expenditure globally
      • 3.2.1.4 Rising awareness regarding early cancer detection
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Stringent regulatory scenarios
      • 3.2.2.2 High cost of diagnostic tests
  • 3.3 Growth potential analysis
  • 3.4 Reimbursement scenario
  • 3.5 Regulatory landscape
  • 3.6 Technological landscape
    • 3.6.1 Core technologies
    • 3.6.2 Adjacent technologies
  • 3.7 Pricing analysis, 2023
    • 3.7.1 By region
    • 3.7.2 By key player
  • 3.8 Future market trends
  • 3.9 Porter's analysis
  • 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Instruments
  • 5.3 Consumables

Chapter 6 Market Estimates and Forecast, By Test Type, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Imaging test
    • 6.2.1 CT scan
    • 6.2.2 MRI
    • 6.2.3 Ultrasound
    • 6.2.4 PET
    • 6.2.5 Other imaging tests
  • 6.3 Biopsy
  • 6.4 Blood test
    • 6.4.1 Liver function tests
    • 6.4.2 Tumor markers
    • 6.4.3 Other blood tests
  • 6.5 Other test types

Chapter 7 Market Estimates and Forecast, By Cancer Type, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Exocrine
    • 7.2.1 Adenocarcinoma
    • 7.2.2 Squamous cell carcinoma
    • 7.2.3 Adenosquamous carcinoma
    • 7.2.4 Colloid carcinoma
  • 7.3 Endocrine

Chapter 8 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospitals and clinics
  • 8.3 Diagnostic laboratories
  • 8.4 Diagnostic imaging centers
  • 8.5 Cancer research institutes

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
    • 9.3.7 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
    • 9.4.6 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
    • 9.5.4 Rest of Latin America
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE
    • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

  • 10.1 Abbott Laboratories
  • 10.2 Agilent Technologies, Inc.
  • 10.3 ASURAGEN, INC.
  • 10.4 Becton, Dickinson and Company
  • 10.5 BioMarker Strategies
  • 10.6 Canon Inc.
  • 10.7 Danaher Corporation
  • 10.8 F. Hoffmann-La Roche Ltd.
  • 10.9 GE HealthCare Technologies Inc.
  • 10.10 Hitachi, Ltd.
  • 10.11 Illumina, Inc.
  • 10.12 Koninklijke Philips N.V.
  • 10.13 Myriad Genetics, Inc.
  • 10.14 Prestige Biopharma Limited (PBP)
  • 10.15 QIAGEN N.V.
  • 10.16 Siemens Healthineers AG
  • 10.17 Sysmex Corporation
  • 10.18 Thermo Fisher Scientific Inc.